Edwards Lifesciences Shares Dip as 355th-Most-Traded Despite Baron Fund Reacquires Stake and TAVR Sales Surge 8.9%

On July 31, 2025, Edwards Lifesciences (EW) closed with a 2.28% decline, trading at $79.42 per share with a volume of $400 million. The stock ranked 355th in trading activity on the day, reflecting mixed investor sentiment amid mixed operational updates.

Baron Health Care Fund’s reacquisition of EW in Q2 signaled renewed institutional confidence in the company’s long-term prospects. Meanwhile, Edwards’ TAVR (transcatheter aortic valve replacement) segment drove revenue growth, with $1.1 billion in Q2 sales, up 8.9% year-over-year, while its heart valve therapies expanded by 61.9%. The firm raised full-year guidance, citing strong performance in structural heart therapies and new product approvals in the U.S. and Europe.

However, leadership changes in the TAVR division, including the departure of key executive Larry Wood, introduced uncertainty. Wood’s transition to Procept BioRobotics raised questions about continuity in Edwards’ innovation pipeline. Additionally, competitive pressures in international TAVR markets remain a risk, despite the company’s recent regulatory wins and product launches.

A backtested trading strategy from 2022 to July 30, 2025, showed that purchasing the top 500 high-volume stocks and holding them for one day generated a 166.71% return, significantly outperforming the 29.18% benchmark. The strategy’s success was attributed to capturing momentum in liquid stocks, highlighting the importance of liquidity and timing in short-term equity performance.